Podcasts about GIP

We talk a lot about weight. We talk a lot about health. But rarely do we talk about them together – even though they're deeply connected. The concept of weight health looks at the bigger picture: hormones, habits, and your body as a whole, rather than separate parts. Ashley Koff, a leading voice in personalized nutrition and author of the newly released book Your Best Shot, brings decades of experience helping people decode how their bodies actually work. She combines science, practical tools, and compassionate guidance to show how to tune into your hunger cues and build a personalized approach to weight health – whether you use GLP-1 medications or not. As the founder of The Better Nutrition Program, Ashley explains how traditional methods and diet culture messaging can be harmful and shares a better way to reclaim trust in your body so you can feel your best.   In this episode, you'll learn: How hormones like GLP-1, GIP, PYY, and CCK influence appetite, cravings, and weight Simple ways to optimize your weight health for lasting results The truth about GLP-1 medications and how they fit into a larger toolkit Experiments and mindset shifts to help you trust your body Tips for navigating triggering diet culture messaging Ashley's "better, not perfect" philosophy and why joy matters This conversation offers a fresh lens to understand your body, make informed choices, and filter out the noise that doesn't serve you. Resources Mentioned: The Biology of Trauma and the Path to Healing (Episode) Learn More about Ashley Koff: Book: Your Best Shot Website: The Better Nutrition Program Instagram: https://www.instagram.com/ashleykoffapproved/ Facebook: https://www.facebook.com/ashleykoffapproved   Learn More about Elise Museles:Get the Food-Mood Bundle Special Podcast Listener Offer Food Story: Rewrite the Way You Eat, Think, and Live Website: elisemuseles.com Instagram: @elisemuseles Facebook: @elisemuseles

I don't think GLP-1 meds are the answer for everyone, but I also don't think they're the villain of the story. For many people they can be genuinely life-changing, when they're used with the right support. So this episode is for anyone who's made that decision (or is seriously considering it) and wants to do it safely, sustainably, and with as much information as possible. -I can't stop you from taking these medications, but I can help you be informed: what to ask, what to monitor, what to eat, and how to protect your muscle, gut, and long-term health along the way.Today's episode is all about one of the biggest health conversations happening right now: GLP-1 medications.I'm joined by Ashley Koff, RD, to give you the straight dope on what's really going on beneath the surface: why so many of us are struggling with food noise, why some people never reach that “80% full” feeling, and what it means when your metabolic switches (the appetite and satiety systems that should be working in the background) aren't firing properly.We break down GLP-1s, starting with what happens in an optimally functioning body: the roles of hormones like GLP-1, GIP, PYY and CCK, and how they influence hunger, fullness, blood sugar, and cravings. We also talk through what side effects might be telling you, what to monitor if you do choose medication, and whether supplements have a role — including the so-called “GLP-1 boosters” you'll see everywhere.Most importantly, this episode is for anyone who wants lasting fat loss and better metabolic health, with or without drugs.Ashley Koff is a registered dietitian and founder of the Better Nutrition Program, and she trains clinicians as course director for UC Irvine's Integrative & Functional Medicine Fellowship. She's also the author of the upcoming book ‘Your Best Shot'.

Send us a textLosing weight after 40 can backfire if it's done the wrong way—and in this episode of the Strong By Design Podcast, we uncover why that matters more than ever. Coach Chris Wilson sits down with Dr. Ron Eccles to explore the growing role of peptides and GLP-based therapies in sustainable weight and fat loss. Dr. Eccles breaks down peptides in simple terms, explaining how gut hormones like GLP-1, GLP-2, and GIP influence hunger, metabolism, and body composition. Together, they discuss why weight loss alone doesn't equal better health—and how preserving muscle, protecting joints, and improving metabolic health must be part of the equation.The conversation also tackles America's declining health outcomes, the concept of the “bliss point” in eating behavior, and what truly happens after you reach your target weight. Dr. Eccles shares insights on emerging peptide technologies, common myths around GLPs, and why lifestyle factors like sleep, movement, and nutrition determine long-term success. You'll also hear real-world lessons from clinical practice, including differences between men and women and the key health metrics that actually matter. This episode is a must-listen for anyone curious about modern weight-loss solutions and how to approach them safely, intelligently, and with long-term health in mind. Time Stamps00:00 – Lose weight the wrong way: Hidden dangers for anyone over 4000:56 — Welcome to the Strong by Design podcast!02:20 – Join Coach Chris and special guest Dr. Ron Eccles03:11 – Dr. Ron's 4 pillars of life balance—and why health is a top priority05:06 – Peptides explained: What they are and how they work06:56 – Discover the peptide that started it all10:38 – GLP-1, GLP-2, and GIP: the gut peptides that silence hunger12:53 – Why losing weight isn't the same as building a better body14:48 - Discussion of the abysmal health outcomes in America16:59 – The concept of the “Bliss Point” explained19:06 – What comes next? 3 options after hitting your target21:02 – Next-level peptides: control appetite, burn fat, and save muscle26:50 – The future of peptides: No injections required29:12 – Debunking myths about GLPs33:30 – How chronic joint pain affected Dr. Eccles's wife36:33 – Weight loss differences between men and women37:56 – The 5 key metrics Dr. Eccles tracks with his clients39:18 – The science behind Alpha Shred revealed43:35 – Lifestyle factors that make peptides work47:02 – Why sleep is essential for brain health53:31 – Key advice before your peptide journey55:39 – Why some “unconventional” doctors get it right1:00:26 - Stay connected beyond the episode with Ron Eccles1:03:23 - Fun fact about the Strong by Design Podcast name1:05:23 - Please share and leave ratings & reviews for the SBD podcast! Resources:15-minute Consultation at 941-799-6583Connect with Dr Ron: InstagramStart the New Year with more Focus, Clarity & Mental Energy!Grab some Neuro-Thrive at a Discount - Use Code: SBD2026

Nutritious Life PodcastIn this timely episode of the Living a Nutritious Life Podcast, we are thrilled to welcome Ashley Koff, RD, a nationally recognized dietitian, author, and nutrition expert.About Our Guest:Ashley Koff, RD, is the founder of The Better Nutrition Program (BNP) and the author of the newly released book, Your Best Shot. An acclaimed weight-health expert and practitioner for more than 25 years, Koff is leading a transformative movement in personalized nutrition, turning “better, not perfect” choices into practical, sustainable strategies that deliver real outcomes.What You'll Learn in This Episode:- The critical role of "weight health hormones" (including GLP-1, PYY, CCK, and GIP) in metabolism, appetite, and overall well-being.- Why weight loss and health have long been separated—and how to finally bridge them for lifelong results.- How optimizing your own hormones is essential, whether or not you use GLP-1 agonist medications.- Why personalized assessment and nutrition matter more than any fad diet, supplement, or one-size-fits-all approach.Episode Highlights:- The science behind the GLP-1 hormone, how GLP-1 agonists work, and why they're reshaping weight health (and medicine!).- Ashley's signature “pizza analogy” to make customizing your nutrition plan simple and sustainable.- The most overlooked nutrients and habits that support your body's own hormonal balance and weight regulation.- A candid discussion about medication, teens, and why every individual needs a personalized approach—plus how Ashley's own story shaped this movement.About Living a Nutritious Life Podcast: Welcome to the Living a Nutritious Life podcast with Keri Glassman, MS, RDN, CDN, where we break down the latest nutrition science into smart, actionable tips to help you live your most nutritious life.On the Living a Nutritious Life podcast, Keri and her world-renowned guests cut through the noise, sharing unparalleled, forward-thinking tips, tricks, and the latest in health, wellness, and nutrition science.Based on Keri's whole-person approach to healthy living, each impactful episode extends far beyond the simplistic “get more sleep” and “eat your greens” advice. She connects the dots like no one else – like how morning yoga can make it easier to choose a healthy lunch, leading to better sleep at night.Listen as Keri and her expert guests explore the physiological and behavioral connections that explain, for example, why the common wisdom around dieting and exercising alone doesn't work, so you can finally make the meaningful changes you've been looking for.Thank you for listening in to this episode of Living a Nutritious Life. We hope you enjoyed the conversation as much as we did! If you found value in this episode, please RATE, REVIEW and SHARE.Ready to Dive Deeper? Are you ready to dive into the world of nutrition and wellness even deeper and become a certified nutrition coach? Join our amazing global community of like-minded students and alumni. Get in on the action—enroll in our Become a Nutrition Coach program at nutritiouslife.com/bnc. Keri has a lot to teach, and we're here to help you get started on your journey!Connect with Ashley on social:IG: www.instagram.com/ashleykoffapprovedWebsite: https://thebetternutritionprogram.com/Your Best Shot: https://thebetternutritionprogram.com/your-best-shot/#OrderConnect with Keri on social: Instagram: https://www.instagram.com/nutritiouslifeofficial/ Instagram: https://www.instagram.com/keriglassman/ TikTok: https://www.tiktok.com/@keriglassman Facebook: https://www.facebook.com/KeriGlassmanNutritiousLife Twitter: https://twitter.com/NutritiousLife_ LinkedIn: https://www.linkedin.com/company/nutritiouslife Pinterest: https://www.pinterest.com/nutritious_life/ Website: https://nutritiouslife.com/ Become a Nutrition Coach: https://nutritiouslife.com/bnc/Copyright © 2023-2025 Nutritious Life.#LivingaNutritiousLife #NutritiousLife Hosted on Acast. See acast.com/privacy for more information.

Happy New Year! This time of the year, most declare their resolutions - a huge majority including diet and weight loss, but what is the best way to do it?In this episode, our Chief Science Officer, Dr. Krista Kostroman, N.D., is joined by Ashley Koff, R.D., the founder of The Better Nutrition Program (BNP), the nutrition course director for UC Irvine's Susan Samueli Integrative Health Institute's Integrative and Functional Medicine Fellowship, and a faculty member at the Integrative and Functional Nutrition Academy (IFNA), where she teaches “An Integrative and Functional Nutrition Approach to Obesity and Weight Management.”She is also the author of the recently released book Your Best Shot (HarperOne, Jan. 6, 2026). With over 25 years of practice, Ashley leads a transformative movement in personalized nutrition — turning “better, not perfect” choices into practical, sustainable strategies that create meaningful health outcomes. Through patient stories and personal experience, she demonstrates that optimal health isn't just possible — it's essential to living a full life.Her work has been recognized widely: she was named one of CNN's Top 100 Health Makers, featured in InStyle as “Hollywood's Leading Dietitian,” and selected as Westin's Global Nutrition Ambassador.Join us today as we uncover the science and truth about weight health and nutrition! This includes the following highlights:What our genetics says about our weight, diet, and nutritionWhat GLP-1s arePersonalized Nutrition and how to create sustainable strategies for optimal health and weight lossHow supplements affect our diet and nutritionAshley Koff's book, “Your Best Shot”If you wish to learn more from Dr. Emily Splichal and Naboso, you may do so through the following channels:Website: https://thebetternutritionprogram.com/about/Instagram: @thebetternutritionprogramCheck out Ashley's book at: Your Best Shot: The Personalized System for Optimal Weight Heath - GLP-1 Shot or Not (Harper One, January 6, 2026). Out now wherever books are soldThe real revolution of the GLP-1 shots is the insight that the body regulates appetite and more with the hormones GLP-1, GIP, PYY, and CCK—and with Your Best Shot in hand, you can learn to optimize their function and your weight health for life______________________________________________________Keep yourself up to date on The DNA Talks Podcast! Follow our socials below:The DNA Talks Podcast Instagram: @dnatalkspodcastThe DNA Company Instagram: @thednacoThe DNA Company's Official Tiktok Account: @thednaco3______________________________________________________Medical Disclaimer: The information provided in this communication is for general informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read here. If you think you may have a medical emergency, call your doctor or 911 immediately.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor tackle a wide-ranging mailbag episode with listener questions from the U.S., UK, and Europe. Topics include unexpected weight regain on GLP-1s, post-meal sleepiness and hypoglycemia, metabolic dysfunction despite normal labs, GLP-1 dosing strategies, and why these medications are about metabolism, not appetite suppression.Key Questions AnsweredWhy can weight regain happen on GLP-1s even when habits haven't changed?How do leptin, ghrelin, injury, stress, and under-fueling affect weight regulation?What does it mean if you get extremely sleepy after meals—is it hypoglycemia?Do GLP-1s increase insulin in a harmful way for non-diabetics?Can you have metabolic dysfunction with normal A1C, cholesterol, and blood pressure?Do GLP-1 medications “wear off,” and how should dosing be adjusted long term?Are GLP-1s just appetite suppressants—or true metabolic treatment?Is it possible to undo decades of calorie counting and restriction-based thinking?What are the risks of the return to extreme thinness in celebrity culture?Key TakeawaysCalories don't explain metabolism. GLP-1 and GIP work across the brain and body—repairing signaling, not just reducing appetite.Leptin matters after dieting. Years of restriction and weight cycling can weaken leptin signaling, making the brain defend weight gain.Fueling is foundational. Medication can't replace adequate food, sleep, and recovery.Post-meal fatigue is a clue. Reactive hypoglycemia is common and often misunderstood.Lowest effective dose wins. GLP-1 success is about pacing, not racing to the max dose.Chasing the “last 10 pounds” can backfire. Cosmetic restriction can create new metabolic problems.Dr. Cooper's Actionable TipsIf weight gain appears after injury or stress, focus first on sleep, regular meals, and full fueling, not restriction.Suspected hypoglycemia? Ask about a mixed meal tolerance test to assess glucose and insulin response.Stay on the lowest GLP-1 dose that's working and adjust only when progress truly stalls.Push back on “appetite suppressant” language—these meds amplify hormones your body already makes.Notable Quote“GLP-1s aren't about eating less—they're about strengthening metabolic signaling” — Dr. Emily CooperLinks & ResourcesPodcast Home: Fat Science Podcast Website – https://fatsciencepodcast.com/Podcast Episode References: https://fatsciencepodcast.com/wp-content/uploads/2025/06/Scientific-References-Fat-Science-Episodes.pdfCooper Center for Metabolism & Fat Science Episodes: https://coopermetabolic.com/podcast/Resources from Dr. Cooper: https://coopermetabolic.com/resources/Submit a Show Question: questions@fatsciencepodcast.comDr. Cooper direct show email: dr.c@fatsciencepodcast.comFat Science breaks diet myths and advances the science of real metabolic health. No diets, no agendas—just science that makes you feel better. This show is informational only and does not constitute medical advice.

Ryan Sternagel—co-founder of The Stern Method, Going Integrative Plus (GIP+), and Our Health Naturally—joins Dr. Karlfeldt to share the real story behind his family's mission: in 2014, Ryan and his wife Teddy learned their son Ryder had stage four neuroblastoma just eleven days before his first birthday. What followed was a crash course in advocacy, research, and resilience—plus a decades-worth of integrative insights earned the hard way. If you've ever felt overwhelmed by a diagnosis, pressured into one path, or unsure how to “do everything” without losing your mind, this conversation is for you.In this episode, Ryan walks through the moment they knew something was wrong, the medical runaround that nearly delayed answers, and how they learned to push for imaging, ask better questions, and make decisions strategically—especially when facing institutional pressure. They discuss the chess match many families experience in pediatric oncology, including navigating treatment expectations, scan decisions, and the importance of building a supportive plan that addresses nutrition, environment, and mindset alongside medical care. Ryan also shares the evolution from documenting their journey online to creating a searchable library of expert integrative oncology guidance through GIP+—so families can learn directly from top holistic cancer doctors and “test-drive” approaches that resonate.You'll also hear Ryan's perspective on “cake vs. frosting”: why foundational daily practices (circadian rhythm, nature time, reducing toxic load, nervous system regulation, and belief/mindset work) often matter more than any shiny new therapy—yet how select advanced tools may fit into a larger integrative strategy. This is a grounded, motivating listen for patients, caregivers, and practitioners who want a more empowered, organized way forward.Key Topics CoveredRyder's stage 4 neuroblastoma diagnosis and the early warning signs that were missedSelf-advocacy in pediatrics: pushing for ultrasound/MRI and trusting intuitionNavigating hospital systems, treatment escalation, and the realities of compliance pressureBuilding an “integrative support stack”: nutrition, juicing, supplements, IV vitamin C, and lifestyleThe importance of organization and implementation: turning information into a workable scheduleNon-toxic living and environmental control (EMFs, chemicals, lighting, plastics, circadian rhythm)Mindset as medicine: trauma work, belief systems, meditation/breathwork, and daily centering practices“Cake vs. frosting”: foundational habits vs. advanced/experimental therapiesRyan's “talent scout” approach: finding top integrative cancer doctors and filtering conflicting infoGIP+ as a model for weekly expert access, Q&A, and a searchable archive of integrative guidanceTo learn more about Ryan and Teddy's work, explore The Stern Method, their step-by-step framework for implementing integrative cancer support in real life, at https://thesternmethod.com/ Listeners can also check out OUR 7, their comprehensive epigenetic nutrient blend from Our Health Naturally, available at https://ourhealthnaturally.com/ use the discount code KARLFELDT20 to receive 20% off from December 16–31, 2025, and KARLFELDT for 10% off ongoing orders after that.For those seeking direct access to top integrative cancer doctors, weekly guidance, and a searchable archive of expert insights, join Going Integrative Plus (GIP+) at https://goingintegrativeplus.com/and use the code KARLFELDT50 for 50% off your first month subscription. -----------------------------------------------A Better Way to Treat Cancer: A Comprehensive Guide to Understanding, Preventing and Most Effectively Treating Our Biggest Health ThreatGrab my book here: https://www.amazon.com/dp/B0CM1KKD9X?ref_=pe_3052080_397514860 Unleashing 10X Power: A Revolutionary Approach to Conquering CancerGet it here: https://store.thekarlfeldtcenter.com/products/unleashing-10x-powerPrice: $24.99100% Off Discount Code: CANCERPODCAST1 Healing Within: Unraveling the Emotional Roots of CancerGet it here: https://store.thekarlfeldtcenter.com/products/healing-withinPrice: $24.99100% Off Discount Code: CANCERPODCAST2-----------------------------------------------Integrative Cancer Solutions was created to instill hope and empowerment. Other people have been where you are right now and have already done the research for you. Listen to their stories and journeys and apply what they learned to achieve similar outcomes as they have, cancer remission and an even more fullness of life than before the diagnosis. Guests will discuss what therapies, supplements, and practitioners they relied on to beat cancer. Once diagnosed, time is of the essence. This podcast will dramatically reduce your learning curve as you search for your own solution to cancer. To learn more about the cutting-edge integrative cancer therapies Dr. Karlfeldt offer at his center, please visit www.TheKarlfeldtCenter.com

A common referral scenario involves hospital clinicians referring a dying patient to hospice. This circumstance gives rise to questions relating to hospice eligibility, the appropriate level of hospice care, and the expectation of the patient and the hospital. In this episode, Husch Blackwell's Meg Pekarske and Bryan Nowicki address these questions and provide insights into effectively managing this situation.Additional resources:Medicare Benefit Policy Manual Chapter 9 Excerpt - General Inpatient Care

In this episode of Diabetes Dialogue, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and co-director of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, share early impressions of topline phase 3 results from the TRIUMPH-4 trial of retatrutide, a once-weekly triple agonist targeting GIP, GLP-1, and glucagon receptors.  Recorded from the ADCES Technology Conference, the conversation frames retatrutide as a potential next step beyond current GLP-1 and dual incretin options, while emphasizing that detailed trial data remain pending. TRIUMPH-4 was a phase 3 study enrolling patients with obesity and osteoarthritis. Topline data suggests participants receiving retatrutide 12 mg achieved a mean weight loss of 28.7% at 68 weeks. Among this population, the trial also reported a 75.8% reduction in WOMAC pain scores from baseline, with approximately 1 in 8 participants reporting complete pain freedom at week 68. Isaacs highlights how striking these figures are in light of the already high bar set by semaglutide and tirzepatide, noting that confirmation in phase 3 heightens anticipation for full publications and future readouts. The hosts connect these findings to evolving clinical priorities reflected in the American Diabetes Association's expanding attention to obesity-related comorbidities, including osteoarthritis, MASLD/MASH, sleep apnea, and kidney disease. They note the broader retatrutide phase 3 program includes studies in type 2 diabetes, moderate-to-severe obstructive sleep apnea, chronic low back pain, MASLD/MASH, and planned cardiovascular and renal outcomes trials. Isaacs underscores the ongoing question of whether benefits across these conditions will be primarily molecule-specific or largely driven by the magnitude of weight loss, particularly given the inclusion of glucagon receptor activity. Safety is discussed cautiously, given the limited nature of top-line disclosures. The hosts note that discontinuation due to adverse events appeared higher with retatrutide than placebo, and they emphasize the need for full reporting on gastrointestinal tolerability and other adverse events. Bellini also points to an intriguing subgroup signal suggesting lower discontinuation rates among participants with higher baseline BMI, while acknowledging this could reflect chance in a modestly sized trial population. Overall, Isaacs and Bellini characterize retatrutide's TRIUMPH-4 update as an important milestone, while stressing that interpretation should remain measured until complete efficacy and safety data are available. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. References: Eli Lilly and Company. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. December 11, 2025. Accessed December 11, 2025. https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-weight-loss-average American Diabetes Association. The American Diabetes Association Launches a New Obesity Division | ADA. diabetes.org. Published June 21, 2024. Accessed December 16, 2025. https://diabetes.org/newsroom/press-releases/american-diabetes-association-launches-new-obesity-division

Listen in as Jay H. Shubrook, DO, FACOFP, FAAFP, and Chrisopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMA, discuss the latest advances in caring for patients with overweight or obesity in the primary care setting, including:The Lancet Commission's new obesity definitions and diagnostic criteriaKey data on incretin-based antiobesity medications like semaglutide and tirzepatideBest practices for patient discussionsStrategies for incorporating new evidence in your primary care practicePresentersJay H. Shubrook, DO, FACOFP, FAAFPProfessor and DiabetologistDepartment of Clinical Sciences and Community HealthTouro University California College of Osteopathic MedicineVallejo, CaliforniaChristopher Weber, MD, FAAP, FACP, CSCS, daBOM, FOMABariatric Services Medical Director, Ascension WisconsinObesity Medicine Director, Ascension Columbia St Mary's Bariatric CenterTrustee, Obesity Medicine AssociationAdjunct Assistant Professor of PediatricsMedical College of WisconsinMilwaukee, WisconsinLink to full program:https://bit.ly/4rG7QQp Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

https://www.otplinks.com 0:00 Welcome & today's focus: Retatrutide and “chasing the biggest number” 1:11 On The Pen intro, live schedule (Mon/Wed/Fri) & housekeeping 2:10 How Dave first heard about retatrutide (work trip, early phase 1 data) 3:35 Flashback clip: early excitement about retatrutide phase 3 trials 4:40 Why this new retatrutide data feels different for obesity medicine 5:32 TRIUMPH-4 trial overview: obesity + knee osteoarthritis population 7:00 Headline results: 28.7% average weight loss, surgery-level efficacy 8:47 Breaking down weight loss by dose (9 mg vs 12 mg; 25–35% loss rates) 11:05 What “efficacy estimate” really means (race-track analogy) 13:28 Real-world view: treatment-regimen estimate (20–23.7%) vs trial ideal 15:40 Mechanism refresher: GIP, GLP-1, glucagon and why RETA differs from TIRZ 18:05 Side effects, dysesthesia/allodynia & who stopped treatment (BMI differences) 21:02 Why the lower doses matter & who actually needs 30% weight loss 24:15 From “just make the scale go down” to quality of weight loss & body composition 28:05 Future focus: health, longevity, and peptides beyond hitting goal weight 30:40 Viewer Q&A: combining RETA + TIRZ, amylin (eloralintide) combos & “talk to your doctor” 34:38 How retatrutide changes the next decade of obesity treatment conversations 37:22 News update: high-dose Wegovy 7.2 mg approval in the EU & US outlook 40:55 Orforglipron oral GLP-1: liver-signal concerns & fast-track FDA review 45:20 Why small-molecule oral GLP-1s aren't the same as injectable peptides 48:40 New topic: Indiana “Safe Drug Act of 2025” and why Dave is concerned 51:02 Production caps, “essentially a copy” language & shifting power from prescribers to FDA 54:28 How the bill undermines personalization while ignoring real safety tools 57:05 Safety theater vs real safeguards: API sourcing, sterility & adverse-event reporting 59:45 Who actually gets hit: compliant 503A/503B compounders vs existing bad actors 1:02:05 Call to action: petition at otplinks.com & why patient voices matter 1:05:10 Change.org impact, media attention & centering the patient perspective 1:07:30 Final Q&A, subscribe, obesity.news email list & closing thanks Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a myriad of transformative advancements and strategic shifts within these industries, illustrating the profound impact of innovation and regulatory changes on healthcare.Eli Lilly's recent strides in obesity treatment highlight a significant scientific breakthrough with their novel drug, retatrutide. Currently in phase 3 trials, this triple agonist targets GLP-1, GIP, and glucagon receptors, achieving an extraordinary 28.7% weight loss in participants. Additionally, it demonstrated a 75.8% reduction in knee osteoarthritis pain. Yet, the journey to this milestone wasn't without challenges. The trials saw a higher discontinuation rate than earlier studies, reminding us of the delicate balance between efficacy and patient tolerability—a consistent theme in obesity pharmacotherapy as developers strive to maximize benefits while minimizing adverse effects.In a testament to the global nature of drug development, Zealand Pharma has embarked on a $2.5 billion collaboration with a burgeoning Chinese biotech firm. This partnership aims to advance oral cardiometabolic therapies, underscoring the crucial role of strategic alliances in accessing innovative scientific platforms and expanding market reach.Rezolute faced a significant setback with a disappointing phase 3 trial for its hypoglycemia treatment, resulting in an 87% drop in stock value. This starkly illustrates biotech's inherent volatility and the critical importance of robust clinical trial design to mitigate financial risks associated with unsuccessful outcomes.Meanwhile, Moderna is leveraging Nanexa's expertise in long-acting formulations to enhance injectable therapy delivery systems. This collaboration is indicative of a broader industry trend focused on optimizing drug delivery technologies to boost efficacy and patient compliance.Operational restructuring is also evident as Pfizer implements cost-cutting measures, including layoffs in Switzerland, as part of broader strategic initiatives to optimize operations amid rising R&D costs and pricing pressures. Simultaneously, Chris Boulton's transition from Amgen to Prolynx underscores the fluid movement of talent within the industry—a reflection of ongoing strategic realignments.Regulatory landscapes are shifting as well. The FDA's approval of the first non-drug at-home treatment for depression marks an expansion into alternative therapeutic modalities beyond traditional pharmaceuticals. This wearable device offers adults with major depressive disorder a novel treatment option, integrating technology into mental health care—a promising addition to holistic treatment strategies.In another significant regulatory update, Teva Pharmaceuticals agreed to delist numerous patents from the FDA's Orange Book following an FTC ruling. This move is anticipated to foster increased generic competition and potentially lower medication costs for conditions like asthma and diabetes—a critical shift towards greater market accessibility.The FDA has also finalized guidance on promotional materials for biologics and biosimilars, standardizing advertising practices to ensure accurate representation of these products' efficacy and safety profiles amidst an expanding biologics market.Moreover, the FDA has launched its Commissioner's National Priority Voucher Pilot Review Program to expedite critical drug approvals. The first beneficiary under this program was USAntibiotics with Augmentin XR, signaling a potential shift towards more rapid access to essential medications.On the international policy front, recent developments between the UK and US have led to reductions in medicine rebate rates within the UK. This adjustment could lead to increased spending on new medicines, indicating more favorable conditions for pharmaceutical Support the show

Book a FREE functional health discovery call HERE. If you've been hearing the buzz about Ozempic, Wegovy, Mounjaro, or other GLP-1/GIP medications, you're not alone. But there's so much more to this conversation than weight loss. In this episode, Tanya breaks down the real science behind GLP-1 receptor agonists — what they are, how long they've been around, and the growing research that shows benefits far beyond the scale. From heart and kidney protection to inflammation reduction and body composition support, Tanya explains what midlife women need to know before jumping on the bandwagon. She also shares her personal journey exploring micro-dosing peptides (including tirzepatide and NAD+) — what she's learning, what's working, and how she's helping women make informed, safe, and personalized decisions through trusted telemedicine partnerships. Whether you're considering GLP-1s, curious about peptides, or simply trying to build energy and longevity in midlife, this episode will help you understand the research, the real benefits, and the importance of building your health on solid foundations. You'll Learn: What GLP-1 receptor agonists are and how they work in the body The long-term research behind GLP-1s — including heart, kidney, and liver health benefits What “micro-dosing” really means (and what we don't yet know) How peptides like tirzepatide and NAD+ may support energy, inflammation, and recovery Why foundational health habits — nutrition, muscle, rest, stress regulation — matter more than any injection or supplement Practical, real-world takeaways for midlife women seeking sustainable health and vitality Disclaimer: This episode is for educational purposes only and should not be taken as medical advice. Always consult with a qualified healthcare provider before beginning or changing any health protocol or medication.   I hope this episode blesses you! Xoxo, Tanya Episode Resources: Episode Catalog   My trusted Supplement Dispensary: Aligned Vitality Fullscript Dispensary My trusted Telehealth Peptide Provider:  EllieMD_Tanya Engesether *I do get a small commission when you use one of the above affiliate links. 3 Ways To Connect With Me: 1️⃣COACHING: Are you READY to Lead Well, Live Well and BE Well? Book a FREE discovery call with me to find out more about functional health coaching. It's the accountability and guidance you need to reclaim your health and happiness! ➡︎ https://alignedvitalityhealth.com/coaching   2️⃣ FACEBOOK: Become part of our Supportive Facebook Group. Connect, share, and learn with others navigating life and leadership ➡︎ https://alignedvitalityhealth.com/community   3️⃣ CONTACT: Leave me a question or comment ➡︎ https://alignedvitalityhealth.com/contact   "Yes! Finally, a podcast helping others become the thriving leaders they're meant to be outside of hustle-culture! This is an amazing resource! Thank you so much for sharing and helping us become Spirit-driven, peaceful leaders!"    If you can relate, please consider rating and reviewing my show! It helps me reach more people – just like you – to help them change their future. Don't forget to follow the show so you don't miss any episodes! And, if you're feeling really generous, I'd be SO honored if you would share this podcast with someone.   Click here to view our privacy policy.   Reminder:  The information you hear on this show is not meant to diagnose, treat, cure or prevent disease.  It is for educational purposes only. Always consult with your own health practitioner before you make any changes to your health.

This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor answer listener questions about BMI cutoffs, weight cycling, metabolic adaptation, trauma, GLP-1 differences, and why some people gain weight on ultra-low calories. Dr. Cooper explains what's really happening inside the metabolic system and why individualized treatment—not dieting—creates sustainable change.Key Questions AnsweredIf my BMI doesn't “qualify” for GLP-1s, is Naltrexone + Bupropion helpful—and what labs matter first?Does being overweight always indicate metabolic dysfunction, and why are U.S. rates so high?If diets damage metabolism, what do you do when you're already 80 pounds overweight?How long does it take for leptin and ghrelin to stabilize with mechanical eating?How can someone gain weight on 1,200 calories/day?After sleeve gastrectomy, how do you eat enough while on a GLP-1?Is set point theory real—and how does the melanocortin pathway influence it?If obesity runs in my family, will I need meds like Zepbound for life?How do trauma and stress alter long-term metabolic health?Can GLP-1s offset weight gain from steroids, mood meds, or hormones?Why might Ozempic work well while Mounjaro causes weight gain?Key Takeaways1. BMI rules don't reflect metabolic truth.A mid-20s BMI can still mask significant dysfunction, especially with weight cycling.2. Weight cycling is metabolically stressful.Repeated losses/regains increase visceral fat, insulin abnormalities, and cardiovascular risk.3. Obesity is a multi-hormonal disease.Most people need pharmacology plus sleep, fueling, and movement—not restrictive dieting.4. Metabolic adaptation is powerful.Under-fueling lowers thyroid output, suppresses fat-burning, and slows metabolism dramatically.5. After bariatric surgery or on GLP-1s, frequency matters.Frequent, nutrient-dense snacks protect muscle, metabolism, and energy.6. Set point changes with better signaling.GLP-1s and related therapies help the brain accurately detect weight and lower the defended level.7. Genetics often mean lifelong support.Family patterns of obesity usually indicate long-term need for metabolic medication.8. Trauma amplifies metabolic risk.Childhood trauma disrupts IGF-1, sleep, stress hormones, insulin, leptin, and ghrelin.9. Medications can cause weight gain—GLP-1s can help counteract it.Steroids, mood meds, hormonal agents, and more can be metabolically unfriendly.10. “Newer” isn't always better.Some people respond poorly to the GIP component in Mounjaro/Zepbound. Individual physiology rules.Dr. Cooper's Actionable TipsRequest deeper evaluation: DEXA, visceral fat, fasting insulin/glucose, leptin, reproductive hormones.Stop restrictive dieting permanently—mechanical eating protects metabolic stability.Work with a fueling-focused dietitian (often ED-trained).Review your medication list for drugs known to cause weight gain.Don't switch GLP-1s or chase higher doses if your current regimen works.Notable Quote“Obesity isn't a willpower problem. It's a metabolic disease, and when the underlying system is supported, the body finally has permission to change.” — Dr. Emily CooperLinks & ResourcesPodcast Home: Fat Science Podcast WebsiteSubmit a Show Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comDr. Emily Cooper on LinkedInMark Wright on LinkedInAndrea Taylor on InstagramFat Science is your source for breaking diet myths and advancing the science of true metabolic health. No diets, no agendas—just science that makes you feel better. The show is informational only and does not constitute medical advice.

Topics We Cover: 00:00 – New data from Harvard/Mass General may classify nearly 70% of adults as having obesity 03:00 – A new oral triple agonist shows record-setting absorption rates 07:00 – Fractal Health's Revita procedure: weight maintenance after stopping GLP-1s 12:00 – Zepbound vial prices drop (full breakdown by dose) 16:00 – Dave's personal experience switching off Mounjaro and intense hunger return 22:00 – Novo Nordisk's EVOKE/EVOKE+ Alzheimer's trial: what the data really means 29:00 – Why GLP-1 neurological research is just getting started 33:00 – Updates on access, partners, and major news coming soon for Medicare patients If you're on Wegovy, Mounjaro, Zepbound, Saxenda, Trulicity, or compounded versions, this episode gives you the insight and context you need to have more competent and confident conversations with your doctor. Bullet Point Summary of the Podcast Episode New Obesity Measurement Data (Harvard/Mass General Study) Harvard and Mass General propose adding waist circumference to BMI to better diagnose obesity. Traditional BMI misses key factors like muscle mass and body composition. Using the updated measure, Americans classified as obese jumps from ~43% to almost 69%. This means 7 out of 10 U.S. adults would now qualify as having the disease of obesity. Dave notes this validates many people who “feel” metabolically unwell despite a “normal” BMI. Reinforces his claim that “most people should be talking to their doctors about GLP-1s.” New Oral Triple Agonist (Ascletis – ASC41/ASC? Molecule) From Ascletis (A-S-C-L-E-T-I-S), developing an oral triple agonist targeting: GLP-1 GIP Glucagon Similar in mechanism to retatrutide, expected around 2027. Preclinical (animal) data show stunning results: Oral bioavailability of 4.2% 9× higher than tirzepatide 30× higher than oral semaglutide 6× higher than oral retatrutide 57× greater drug exposure than oral retatrutide Half-life ~56 hours Stronger receptor activation than retatrutide in vitro Suggests potential for the first powerful oral triple agonist—worth watching. ️ 3. Discussion of the Gray Market / TikTok Experience Dave briefly recounts losing his TikTok account and landing in an algorithm filled with teenagers promoting gray-market “retatrutide.” Expresses concern over unregulated peptide sales, especially to minors. Fractal Health's New Data – Weight Maintenance After Stopping GLP-1s New results from the Reveal One study (Fractal Health). Participants: lost 24% of body weight on GLP-1s → stopped injections → got one Revita procedure. At 6 months post-GLP-1 discontinuation: Weight changed only 1.5% (vs. ~10% regain in typical off-drug trials) HbA1c barely shifted Safety profile clean Suggests possible long-term weight maintenance without injections through gut mucosal re-lining. Dave describes his own recent attempt to switch drugs and significant hunger return. Food Noise & Biologic Hunger Dave discusses how stopping Mounjaro caused terrifying, primal hunger. Describes the distinction between: Food noise (brain-based thoughts) Hunger signals (biological/animalistic) Reinforces why many patients cannot maintain weight loss without support. Zepbound (Tirzepatide) Cash-Pay Price Reductions Eli Lilly drops cash-pay vial pricing: 2.5 mg: $349 → $299 5 mg: $499 → $399 7.5–15 mg: $499 → $449 Community feedback (informal poll): Most say still too high to leave compounded versions. Many would switch to branded if price hit $200–$300. Dave notes the Most Favored Nations agreement will push GLP-1 prices toward $250/month within 24 months. Alzheimer's Study (Novo Nordisk – EVOKE & EVOKE+) Oral semaglutide (Rybelsus, 14 mg) did not slow Alzheimer's clinical progression. Biomarkers improved but daily function and cognitive decline did not improve vs placebo. Important context: Oral Rybelsus is a weak form of semaglutide; stronger versions (like Wegovy 2.4 mg or upcoming high-dose oral Wegovy) not tested. Weight loss is not desirable in Alzheimer's patients, influencing drug selection. Dave emphasizes: This was a nearly $700M trial and an act of scientific courage. This is NOT the end of GLP-1 Alzheimer's research. Future molecules may target neurological pathways without suppressing appetite. Mentions Lilly's brenipatide, a GIP receptor agonist being developed for: Addiction Opioid dependency Possibly asthma ️ 8. Access, Cost, and Patient Empowerment Highlights Shed as a partner offering telehealth GLP-1 access. Notes many patients hide GLP-1 use from their primary care doctors. Reinforces OTP's mission: better, more honest conversations with clinicians. Shapa (Numberless Scale) & Dave's Personal Update Dave explains how the Shapa numberless scale helped him stay engaged during weight fluctuations. Finds stepping on “zones” (green/gray/blue) less emotionally damaging than numbers. Closing Notes Promises upcoming Eli Lilly savings card update. Encourages subscribing, liking, and enabling notifications for algorithm visibility. Thanks OTP community for amplifying patient-centric obesity medicine news. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Today's episode is a powerful, honest conversation with three incredible women who are taking their health into their own hands. Joined again by the brilliant Kimberly Cunningham, NP, we're talking about what it really looks like to reclaim your body, your confidence, and your joy after 40.Elizabeth, Andrea, and Orion share their deeply personal journeys with hormone replacement therapy and GLP-1/GIP weight-loss medications, what led them to seek help, what changed, what surprised them, and how their lives have transformed physically, mentally, and emotionally.This roundtable is honest, tender, eye-opening, and full of information that women are rarely given. If you've ever struggled with weight, mood swings, fatigue, food noise, or that feeling of “I don't recognize myself anymore,” this episode will feel like a breath of fresh air.Kimberly also breaks down the science behind GLP-1/GIP medications, HRT, PCOS, perimenopause, metabolic health, insurance barriers, and the stigma so many women carry, when the truth is, this is biology, not moral failure.This is the conversation I wish I had decades ago. And I hope it helps you feel seen, validated, and supported on your own path.Go to michellefox.com/podcast for full show notes. Hosted on Acast. See acast.com/privacy for more information.

Today, we're diving into a topic that has been everywhere lately in your social feed, at brunch with your girlfriends, and even in doctors' offices. Yep… we're talking Mounjaro, Ozempic, and weight loss medications.And let me just say this upfront:- There is zero judgment here.- This episode comes from a place of love, education, and empowerment.Because the truth is… so many women are being prescribed these medications without being told how they actually work, what changes happen inside the body, or how to avoid regaining all the weight later.So today, I'm giving you the full picture — simply, clearly, and without the hype.What We Cover in This Episode1. What Mounjaro actually does in your bodyI break down how this medication mimics two natural gut hormones (GLP-1 and GIP) and how that affects your hunger, fullness signals, digestion, and blood sugar — without boring you with unnecessary science.2. Why it reduces hunger and cravings so dramaticallyYou'll hear the three main physiological effects women feel immediately when they start the medication, and why many describe it as “finally having the food noise turned off.”3. The real reason people lose weight on it (hint: it's not magic)It's not a miracle drug, but it does make being in a calorie deficit much easier because you're simply not as hungry. The medication supports the process… but it doesn't do the work for you.4. Why you may regain the weight quickly if you stopThis part is SO important.If you don't build the right habits, eating structure, and mindset while using the medication, the weight can return extremely fast once you come off it.That's why I work with women who are taking these medications, because the foundation still matters.5. Who Mounjaro is and isn't designed forYou'll learn: ✔ When it can be truly helpful ✔ Why doctors aren't having the full conversation ✔ Why structure, mindset, and habits matter just as much — if not more — than the medication itself6. How to get the same effects without medicationYes - it's possible.In this episode, I explain how food, structure, protein, balanced meals, and lifestyle habits can naturally help regulate hunger, stabilize blood sugar, and reduce cravings… without injections, side effects, or huge costs.

In this bonus episode of A Friend for the Long Haul, I get to talk with Dr. Julia Moore Vogel from Scripps Research. I slid into her DMs to see if she'd like to join me to discuss the recruitment and structure of a new clinical trial examining the effects of tirzepatide, a dual GLP-1 and GIP agonist, on long COVID symptoms. Dr. Vogel is the Senior Program Director, The Participant Center, All of Us Research Program. She's a fellow long hauler and "manages The Participant Center (TPC) for the All of Us Research Program which is charged with recruiting and retaining 350,000 individuals that represent the diversity of the United States. TPC aims to make it possible for interested individuals anywhere in the US to become active participants, for example by collaborating with numerous outreach partners to raise awareness, collecting biosamples nationwide, returning participants' results and developing self-guided workflows that enable participants to join whenever is convenient for them." (Thanks for letting me borrow the blurb, Scripps.

Doctor Mau Informa ®️#drmauinforma Mounjaro (Tirzepatida): ¿Magia o Ciencia?

Precise receptor mapping is reshaping how we understand incretin biology. David Hodson explains how GPCR-targeted chemical probes reveal where GLP-1 and GIP receptors actually signal across pancreas and brain—and what this means for metabolic drug design.Learn how these tools refine gpcr drug discovery, clarify receptor internalization, and guide next-gen therapeutics.

Welcome to Ozempic Weightloss Unlocked, where we decode the latest breakthroughs, news, and hidden truths about one of the world's most talked-about weight loss drugs. Today, the buzz is about change—how new research, fresh delivery methods, and evolving regulations are reshaping the Ozempic story. Let us start with what is most recent. There is a big development: needles may no longer be necessary. According to reporting in Popular Mechanics and new data published in The New England Journal of Medicine, Novo Nordisk, the maker of Ozempic and Wegovy, has released results for a daily oral version of semaglutide, the active ingredient in Ozempic. In their clinical trial, this pill matched the weight loss produced by the weekly injection, with an average of 16.6 percent reduction in body weight. About a third of participants lost more than 20 percent. While side effects like nausea and vomiting were reported at higher rates than placebo, this new pill could make using these drugs more accessible than ever.Access is also the hot topic in pricing. Until this year, monthly Ozempic prescriptions could cost up to $1,350 without insurance support. But after new negotiations, many users will soon pay $50 to $350 per month, depending on dosage and coverage. Lower prices are expected to make these drugs far more widely available.So, how well does Ozempic stack up in its primary role? Ozempic was first approved to treat type two diabetes, with weight loss as a major secondary effect. Harper Clinic Utah reports that, in clinical trials, people using Ozempic lost on average between 10 and 15 percent of their body weight over a little more than a year. But real world success depends on how consistently people use it and whether they also improve their diet and exercise habits.Now a common question—how does Ozempic compare to newer weight loss options like Zepbound and Wegovy? The main distinction is the active ingredient. Ozempic uses semaglutide, which triggers the body to release the hormone GLP-1, helping you feel fuller and slow digestion. Zepbound uses tirzepatide, which mimics both GLP-1 and a second hormone called GIP, and results from major trials suggest it can lead to more dramatic weight loss—up to 21 percent of body weight in some studies. However, Ozempic remains covered by insurance for diabetes, while Zepbound is less often covered.Beyond weight, a new area of research is exploring how Ozempic could affect long-term health conditions. According to ScienceDaily, a recent large-scale analysis found that when people stop using prescription weight loss drugs like Ozempic, they tend to regain much of their lost weight, underscoring the need for ongoing treatment or lifestyle change. But these medicines may do much more than affect weight. Recent studies at University of California San Diego found that people with colon cancer who were on GLP-1 drugs were less than half as likely to die within five years. Another new UVA study, covered by Fox News and ScienceDaily, points to dramatically lower death rates in cancer patients who use GLP-1 drugs like Ozempic—potentially because they lower inflammation and improve metabolic health.There is also new investigation about Ozempic's possible use in treating long COVID. According to research covered by ClickOnDetroit, anecdotal reports suggest that some people taking GLP-1 drugs for weight loss also experienced improvement in their post-COVID symptoms, and new clinical trials are underway.Despite these major advances, affordability and access remain challenges. The latest KFF Health Tracking Poll says that about one in eight adults in the United States are now taking a GLP-1 medication like Ozempic, Wegovy, or Zepbound. But half of those surveyed still find the drugs financially out of reach, even as prices are starting to come down.What does all this mean for lifestyle and health? The current scientific consensus is clear: these drugs do not replace needed changes in eating habits and physical activity. As physicians emphasize, Ozempic works best as part of a treatment plan that includes real lifestyle change.As you can see, Ozempic and drugs like it are not just a story about slimming down—they are opening doors to better health, new medical research, and greater access for millions. Thank you for tuning in to Ozempic Weightloss Unlocked. Make sure to subscribe so you do not miss the next episode covering the evolving science and your questions about Ozempic and weight loss. This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Send us a textChris Broomhead is a bodybuilder, personal trainer and coach, educator, entrepreneur, and advocate for science-backed performance & health. After 14+ years competing in bodybuilding, he is now dedicated to cutting through hype in health and performance.Today, Chris focuses on GLP-1s and peptides, such as Semaglutide, Tirzepatide, Retatrutide, teaching how science and lifestyle work together for resilience, longevity, and transformation.Find Chris at-IG- @Chris_Broomhead_researchYT- @Chris Broomhead CoachingFind Boundless Body at- myboundlessbody.com Book a session with us here!

Solar Dominates 2025 Energy Additions; Nuclear Sees Major Expansion Welcome to our weekly Renewable Energy Briefing! Stay informed on the latest industry trends.  Episode #38 Briefing Highlights: -U.S. government and Westinghouse in $80 billion deal for new nuclear power  -Global Infrastructure Partners (GIP) in a massive deal to acquire utility giant AES  -New federal report shows solar made up almost three-quarters of all new power in 2025 (19GW) -Federal government cancels $7 billion for low-income solar; over 20 states are now suing Solar continues its dominance in 2025, accounting for 19 GW of the 26 GW of new U.S. energy capacity added this year. Meanwhile, the nuclear renaissance accelerates as the U.S. government and Westinghouse announce an $80B deal that reshapes the future of baseload power. Benoy and David break down the biggest transactions—including GIP's acquisition of AES—and the implications of federal policy changes, such as the Trump administration canceling $7B in solar grants aimed at low-income communities. Get the clean energy insights you need in five minutes. Join us for a comprehensive analysis that combines expert commentary with up-to-the-minute news, offering you a strategic overview of the renewable energy market. Don't miss out on the crucial details that can impact your investment decisions. Tune in weekly for your essential dose of Renewable Energy insights! Host Bio: Benoy Thanjan Benoy Thanjan is the Founder and CEO of Reneu Energy, solar developer and consulting firm, and a strategic advisor to multiple cleantech startups. Over his career, Benoy has developed over 100 MWs of solar projects across the U.S., helped launch the first residential solar tax equity funds at Tesla, and brokered $45 million in Renewable Energy Credits (“REC”) transactions.   Prior to founding Reneu Energy, Benoy was the Environmental Commodities Trader in Tesla's Project Finance Group, where he managed one of the largest environmental  commodities portfolios. He originated REC trades and co-developed a monetization and hedging strategy with senior leadership to enter the East Coast market.   As Vice President at Vanguard Energy Partners, Benoy crafted project finance solutions for commercial-scale solar portfolios. His role at Ridgewood Renewable Power, a private equity fund with 125 MWs of U.S. renewable assets, involved evaluating investment opportunities and maximizing returns. He also played a key role in the sale of the firm's renewable portfolio.   Earlier in his career, Benoy worked in Energy Structured Finance at Deloitte & Touche and Financial Advisory Services at Ernst & Young, following an internship on the trading floor at D.E. Shaw & Co., a multi billion dollar hedge fund.   Benoy holds an MBA in Finance from Rutgers University and a BS in Finance and Economics from NYU Stern, where he was an Alumni Scholar. Connect with Benoy on LinkedIn: https://www.linkedin.com/in/benoythanjan/ Learn more: https://reneuenergy.com https://www.solarmaverickpodcast.com     Host Bio: David Magid David Magid is a seasoned renewable energy executive with deep expertise in solar development, financing, and operations. He has worked across the clean energy value chain, leading teams that deliver distributed generation and community solar projects. David is widely recognized for his strategic insights on interconnection, market economics, and policy trends shaping the U.S. solar industry. Connect with David on LinkedIn: https://www.linkedin.com/in/davidmagid/   If you have any questions or comments, you can email us at info@reneuenergy.com.  

Perchè Vincenzo Lanni, l'accoltellatore di piazza Gae Aulenti era libero di circolare nonostante i precedenti di pericolosità? Davanti al Gip che ha convalidato l'arresto ha detto di aver scelto una vittima a caso in un luogo simbolo del potere economico. Ne parliamo con il suo legale. Ci occupiamo poi di una norma di Regione Piemonte ritenuta dal Tribunale di Torino discriminatoria verso gli stranieri perchè prevede per loro l'assegnazione di una casa popolare solo in presenza di un contratto di lavoro. Infine riflettiamo sul caso di Siska, la ragazza di 26 anni belga morta a seguito di eutanasia perchè sofferente di depressione e sindrome post-traumatica.

Today, we're tackling a question that comes up often in peptide, weight loss, and nutrition clinics: why does one person see great results with semaglutide, while another responds better to tirzepatide—or even retatrutide? If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. https://pepties.com/partners/ All three peptides target the incretin system, but they act in slightly different ways—and those differences can dramatically affect outcomes. Let's start with the basics. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist. It mimics the gut hormone GLP-1, which increases insulin when blood sugar is high (to help lower blood sugar), suppresses glucagon (which also decreases blood sugar), and slows gastric emptying. It also enhances satiety—so you feel full longer and eat less. Tirzepatide is a dual agonist, acting on both GLP-1 and GIP receptors. GIP—glucose-dependent insulinotropic polypeptide—also helps with insulin secretion to lower blood sugar, increases fat metabolism, and may reduce some of the GI side effects seen with GLP-1 alone. Retatrutide, the newest in the lineup, is a triple agonist that targets GLP-1, GIP, and glucagon receptors. Retatrutide lightly activates the glucagon receptor while strongly activating GLP-1 and GIP receptors, which help regulate blood sugar and boost insulin secretion. This keeps blood sugar stable—or even improves it. Beyond blood sugar, glucagon also ramps up metabolism and calorie burning. By gently engaging glucagon receptors, retatrutide can increase energy expenditure and support fat loss without triggering large blood sugar spikes. So how do you decide which one might work best? Let's walk through common clinical situations. Patients with Hypothyroidism Let's talk about hypothyroidism. People with hypothyroidism often have slower metabolism, making weight loss more difficult even with a balanced diet. Low thyroid hormone levels slow calorie burning and energy use, so weight gain can occur more easily. For these patients, semaglutide is a reliable starting point—it helps regulate appetite and caloric intake. If progress plateaus, tirzepatide or retatrutide may provide an edge by boosting energy expenditure and fat oxidation, essentially "jump-starting" a slower metabolism. Patients with PCOS (Polycystic Ovary Syndrome) What about patients with PCOS (polycystic ovary syndrome)? Insulin resistance is common in PCOS, often leading to higher androgen levels (e.g., testosterone) and symptoms like irregular periods, acne, and excess hair growth. Hormonal changes also affect appetite-regulating hormones, increasing hunger and cravings. Both GLP-1 and dual agonists have proven effective in managing metabolic and reproductive aspects of PCOS. Typically, we start with semaglutide to improve weight, insulin sensitivity, androgen levels, and menstrual regularity. After a few months, if weight loss plateaus or cravings remain high, we may switch to tirzepatide. The added GIP activity enhances fat metabolism, insulin control, and may further support hormone regulation and ovulation. The key is starting with what's well-studied and tolerated, then stepping up if additional metabolic or reproductive support is needed. Type 2 Diabetes (T2DM) The next medical condition I'd like to talk about is type 2 diabetes (T2DM). Weight gain in T2DM often stems from insulin resistance. Cells don't respond effectively to insulin, prompting the pancreas to relelase more. High insulin levels encourage fat storage, particularly around the abdomen, while elevated blood sugar can increase hunger and cravings. Some diabetes medications, like insulin or sulfonylureas (e.g., glipizide or glyburide), can also contribute to weight gain. All three drugs lower blood sugar and promote weight loss, but tirzepatide currently shows the strongest combined A1c reduction (average blood sugar over the past 2 to 3 months) and weight loss. GIP and GLP-1 work together to enhance insulin response more effectively than GLP-1 alone. Retatrutide is in phase 3 trials, with potential FDA approval as early as 2027. Its glucagon receptor activity may offer additional glucose regulation and energy expenditure benefits. Patients with >15% Weight Loss Goals Okay, let's talk about weight loss goals and how this ties into the decision process for choosing a weight loss medication. For those patients looking to lose more than 15% of their total body weight, tirzepatide or retatrutide are likely to deliver greater results. Clinical data show semaglutide can achieve up to 15% total weight loss while tirzepatide can achieve up to 22% and retatrutide up to 24%. That said, semaglutide remains a highly effective option for weight loss. However, if progress begins to plateau, transitioning to a dual or triple agonist may help restart weight loss and push past that plateau. Pre- and Postmenopausal Women What about peri- and postmenopausal patients? Hormonal shifts during perimenopause and menopause slow metabolism and can increase cravings. Declining estrogen promotes abdominal fat storage and affects appetite-regulating hormones. Semaglutide helps with appetite control and gradual fat loss, while tirzepatide's GIP activation can further support fat metabolism when estrogen levels drop. Patients with Heart Disease or High Cholesterol The last group of patients I'd like to discuss is patients with heart disease (e.g., heart failure, stroke, heart attack, or even atherosclerosis) or people with high cholesterol. Semaglutide has the strongest cardiovascular outcomes data, reducing major adverse cardiac events by 20% and improving LDL cholesterol (bad cholesterol) and blood pressure. Tirzepatide shows promise for heart and lipid benefits, but those trials are still ongoing. For patients with prior heart attack, stroke, or severe coronary artery disease, semaglutide remains the safest evidence-backed starting point—unless intolerable side effects or weight loss resistance occur. Tolerability Now I want to switch gears a bit and talk about side effects and tolerablity of these peptides. Some patients experience stomach-related side effects like nausea, bloating, or acid reflux on semaglutide. Generally, tirzepatide tends to cause fewer GI side effects, likely due to GIP balancing GLP-1 activity in the gut. So patients struggling with nausea or other stomach-related side effects may find tirzepatide more tolerable. Just something to keep in mind. Individualizing Therapy Lastly, I want to highlight the importance of individualizing weight loss peptide treatments. There's no one-size-fits-all approach when it comes to these therapies. Clinicians should carefully consider a patient's goals, medical history, current medications, and tolerance before choosing the most appropriate option. Setting realistic expectations from the start is essential. It's important to remember that everyone's body responds differently because of factors like hormones, genetics, metabolism, gut microbiome balance, and lifestyle habits. These differences influence how effectively a peptide therapy works and how well it's tolerated. That's why ongoing monitoring and follow-up are such an important part of the process. Providers track progress, adjust dosing when needed, and switch medications if weight loss plateaus or side effects occur. The goal isn't just to lose weight quickly—it's to create a safe, sustainable plan that supports long-term metabolic health and helps patients feel their best. Thanks for listening to The Peptide Podcast.  If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. Until next time, be well, and have a happy, healthy week.

Today we're talking about peptides being researched for addiction. We'll unpack the science behind the incretin system, how those pathways tie into reward and substance use, and focus in on the newest triple‐agonist retatrutide. We'll also look at early evidence for alcohol, tobacco and other substance-use disorders when using certain peptide therapies. If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going. https://pepties.com/partners/ What are GLP-1, GIP and the “dual/triple” agonists? First, let's review some biology to ground the discussion. GLP-1 (glucagon‐like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) are incretin hormones. Incretins are gut hormones that help with digestion and blood sugar control. They're released by the gut in response to food.  GLP-1 raises insulin levels after you eat to help lower blood sugar, slows gastric emptying, and reduces appetite. It also reduces how much glucagon your body makes. This helps to lower your blood sugar. Medications like semaglutide and dulaglutide work by mimicking GLP-1 and are often referred to as “GLP-1 agonists”. GIP has somewhat overlapping but distinct roles from GLP-1. It too, influences insulin secretion, but it also helps with fat metabolism.  In a nut shell, GIP helps fat cells respond more efficiently to insulin so they release stored fat to be used as energy when your body needs it. This process helps your metabolism shift from just storing energy to burning fat for fuel. Medications like tirzepatide work by mimicking both GLP-1 and GIP and are often referred to as “dual” agonists.  When GIP and GLP-1 are activated together — like in tirzepatide — they work as a team: GLP-1 helps control appetite and slow down digestion. GIP boosts how your body handles insulin and energy. Together, they help reduce hunger, improve metabolism, and burn fat more efficiently. Now here's where it gets a bit tricky.  A newer medication that's still in development, retatrutide, works on three hormone pathways: GLP-1, GIP, and glucagon receptors. It's called a “triple agonist”, and even though it activates the glucagon receptor, it doesn't cause high blood sugar like you might expect. It's about balance. In type 2 diabetes and obesity, the body's hormone signals are out of balance. Retatrutide gently activates the glucagon receptor, but at the same time it strongly activates GLP-1 and GIP receptors — which still help control blood sugar and increase insulin. So blood sugar stays stable or even improves overall. Glucagon doesn't just affect blood sugar — it also increases metabolism and helps the body burn fat and calories. By slightly stimulating glucagon receptors, retatrutide can boost energy use and promote fat loss without causing big spikes in blood sugar. As a result, you get the blood sugar control of GLP-1 and GIP, plus the fat-burning benefits of glucagon activation — leading to even greater weight loss and metabolic improvement.  Right now, retatrutide is in phase 3 clinical trials, which are the final stage of testing before approval. These studies are expected to finish in early 2026, and if results look good, the FDA could approve retatrutide as early as 2027.  Addiction Why is this relevant for addiction? Because the gut-brain axis, reward circuitry, and the pathways that regulate “wanting/consuming” food overlap with those involved in substance use.  Appetite, reward, and craving may share neural substrates (dopamine, GABA, mesolimbic system) and so a drug that reduces drive to eat might also modulate drive to drink, smoke or use other substances. The link between GLP-1/related drugs and substance use disorders  Let's now dive into what the research says about GLP-1 receptor agonists (and related medications) in the context of alcohol, tobacco, and other substances. Let's start with what we know from animal research. In pre-clinical studies, scientists have found that GLP-1 receptor agonists seem to change how animals respond to addictive substances. A systematic review showed that in rodents, treatment with GLP-1 drugs reduced the behavioral effects of alcohol, nicotine, amphetamine, and cocaine. For example, one GLP-1 drug called exendin-4 reduced alcohol-related behaviors in rodents. And even more recently, a study in both male and female rats showed that giving semaglutide, tirzepatide, or even retatrutide, reduced alcohol discrimination, meaning the rats didn't experience the same “feeling” from alcohol as before. This means that the “interoceptive stimulus effects” or the internal sensations — how alcohol feels inside the body, changed. This is really important because this is what often drives people to drink or relapse. So, if these medications can blunt those internal cues, it suggests they might disrupt the rewarding effects of alcohol that help maintain addiction. When we shift to human studies, things get even more interesting. A systemic review found that out of five studies looking at GLP-1 receptor agonists in people with substance use disorders — mostly alcohol and nicotine — three showed real reductions in substance use, while two did not. In one large observational study of over 150 adults with obesity who drank alcohol, those who were taking semaglutide or tirzepatide for at least 30 days reported fewer drinks, fewer binge episodes, and lower overall intake compared to people not on those drugs. A phase 2 clinical trial of once-weekly semaglutide in adults with alcohol use disorder showed similar results — lower alcohol craving and some reductions in drinking behavior. There's also data from a massive registry-based study showing that people with alcohol or opioid use disorder who were prescribed GLP-1 or GIP drugs had 50% lower rates of alcohol intoxication and a 40% lower rate of opioid overdose. Still, experts are cautious — meta-analyses and reviews consistently note that the evidence, while promising, is still early and we don't yet have large, long-term randomized controlled trials. What's Going On? So, what's actually happening inside the brain and body that could explain these changes in craving and reward? How can medications originally made for diabetes and/or weight loss end up helping with addiction?” Mechanistically, GLP-1 drugs may affect the brain's reward system — especially dopamine signaling in areas like the nucleus accumbens — and reduce the “wanting” of reward substances like food or alcohol. They might also calm stress responses and make relapse cues less powerful. And there are probably some physical effects too — things like slower digestion and increased fullness, which might make it harder to physically consume large amounts of alcohol or even smoke as much. But again, many of these findings come from animal models, which don't always perfectly reflect human addiction. Most of the focus so far has been on alcohol, though there's also some early evidence that GLP-1 drugs might influence nicotine use. For substances like opioids or cocaine, the data is thinner and more mixed. Bottom line — at this stage, GLP-1 receptor agonists, and maybe even GIP/GLP-1 dual agonists, represent a really promising new direction for treating addiction — but it's still early days. We also don't yet have human addiction studies on retatrutide, pre-clinical data in rats show that, like semaglutide and tirzepatide, it too, reduces alcohol discrimination. In practical terms, if you're treating patients with obesity or diabetes who also struggle with alcohol or nicotine use, choosing a GLP-1 or dual agonist might offer an unexpected bonus — helping with cravings. It also gives us a new way to talk with patients about how metabolism, reward, and craving are all interconnected. But — and this is important — the data are still limited. Most studies are small, short, and often focus on people with obesity or metabolic disease rather than pure addiction. So, for now, it's an adjunctive idea, not a replacement for established therapies. We'll need larger randomized trials in people with substance use disorders to really understand who benefits, what doses work, and how long the effects last. Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend, please share this episode! Until next time, be well, and as always, have a happy, healthy week.

Hitting a metabolic wall in midlife? You're not alone — and you're not broken. In this episode, Michele Folan, midlife health coach and former diabetes industry insider, breaks down the science (and the truth) behind microdosed GLP-1 and peptide therapy for women 40+.Drawing on many years in diabetes and cardiovascular health, Michele explains how incretin hormones like GLP-1 and GIP regulate appetite, satiety, and insulin sensitivity — and why they've become game-changers for both metabolic and weight health. You'll hear:The wild origin story of GLP-1 (hint: it starts with the Gila monster)Why early GLP-1 drugs revolutionized diabetes careHow microdosing protocols now support fat loss while protecting lean muscleThe real goals: improved A1C, fasting insulin, lipids, inflammation, and energyThis isn't about shortcuts — it's about layering science-backed tools onto strong habits: ✅ Lifting heavy ✅ Eating enough protein ✅ Prioritizing recovery ✅ Partnering with trusted, physician-led telehealth and vetted compounding pharmaciesMichele also dives into other longevity peptides that support sleep, recovery, cognition, skin, and hair health — plus the role of NAD+ in cellular repair and energy.If you've been “doing everything right” and still feel stuck, this episode connects the dots between modern peptide therapy and midlife metabolism — with zero hype and total transparency.

Can medications like Ozempic and Mounjaro actually do more than help you lose weight? This minisode features highlights from our full conversation, which premiered October 7th, 2025. Watch the full episode here → https://youtu.be/AcVIiy201H4?si=nlaFL3JnoZHxQVFh Dr. Rocio Salas-Whalen and I explore the difference between GLP-1, GIP, and triple-agonist drugs — and what's next in obesity medicine, how estrogen changes after 40 drive midsection weight gain and inflammation, why GLP-1s reduce cancer and Alzheimer's risk through anti-inflammatory and neuroprotective effects and how obesity and insulin resistance impact fertility and PCOS — and how GLP-1s can help.If you've ever wondered whether GLP-1s are just “weight loss shots” or a real step forward in metabolic and brain health — this “minisode” is a must-listen. *** Follow Dr. Salas-Whalen: Instagram: @drsalaswhalen TikTok: @drsalaswhalen @strengthmd @thedryrevolution *** I'm Louisa Nicola — clinical neuroscientist — Alzheimer's prevention specialist — founder of Neuro Athletics. My mission is to translate cutting-edge neuroscience into actionable strategies for cognitive longevity, peak performance, and brain disease prevention. If you're committed to optimizing your brain — reducing Alzheimer's risk — and staying mentally sharp for life, you're in the right place. Stay sharp. Stay informed. Join thousands who subscribe to the Neuro Athletics Newsletter → https://bit.ly/3ewI5P0 Instagram: https://www.instagram.com/louisanicola_/ Twitter : https://twitter.com/louisanicola_ Topics discussed: 00:00 – Intro 00:04  – The Probiotic GLP-1 Myth 00:19 – The “iPhone Evolution” of GLP-1 Drugs 00:52 – GLP-1 vs GIP vs Triple Agonists Explained 01:24 – Phase 3 Results & Massive Weight Loss Outcomes 01:38 – The Role of Glucagon in Weight Loss 01:56 – Menopause, Estrogen & Midlife Weight Gain0 3:06 – The “Fat Shift” After 40 04:01 – Can You Combine HRT and GLP-1s? 06:17 – “Willpower” vs Biology in Obesity 07:49 – The Genetic and Hereditary Roots of Obesity 08:57 – Breaking the Transgenerational Cycle 09:30 – Thyroid Cancer Myths and GLP-1 Safety 10:49 – GLP-1s and Breast Cancer Prevention 12:06 – Inflammation as the Root of Disease 12:28 – Neuroprotection and Alzheimer's Prevention 13:17 – GLP-1s, PCOS & Fertility Benefits 13:53 – The Positive Ripple Effect on Mental Health 14:21 – GLP-1s Reduce Alzheimer's Risk by 33% 14:58 – The Future of Metabolic Health Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Let's dive into the latest news shaping this dynamic industry.Bristol Myers Squibb recently made headlines with their acquisition of Orbital Therapeutics for a remarkable $1.5 billion. This strategic move is aimed at enhancing their in vivo cell therapy capabilities, particularly in treating autoimmune disorders. In vivo cell therapy is a pioneering approach that allows genetic modifications directly within a patient's body, potentially revolutionizing the treatment landscape for numerous conditions. This acquisition underscores Bristol Myers Squibb's commitment to pushing the boundaries of innovative cell therapy technologies and reflects a broader trend in the industry towards personalized medicine.In another significant development, AstraZeneca has aligned with the Trump administration's Most Favored Nation pricing program, agreeing to provide Medicaid drugs at prices competitive on a global scale. This decision marks a strategic shift towards cost reduction, especially in chronic disease management and respiratory therapeutics. The move is indicative of AstraZeneca's efforts to adapt to regulatory pressures and evolving policies that emphasize value-based healthcare delivery.Meanwhile, Ypsomed has announced plans to invest $248 million in establishing a manufacturing facility in North Carolina. This facility will focus on producing auto-injectors, essential for treating diabetes and metabolic disorders. The investment signifies a strategic operational expansion aimed at meeting rising demand in North America, highlighting the growing importance of drug delivery devices in the therapeutic landscape.Turning to clinical trials, Regeneron has unveiled promising Phase 1/2 data for its DB-OTO gene therapy targeting genetic hearing loss in children. By using AAV vectors to address DFNB9-related synaptic transmission deficits, this therapy could mark a breakthrough for those suffering from hereditary hearing conditions. Satellos has also presented encouraging Phase 1 results for SAT-3247, an oral small molecule targeting AAK1 in Duchenne muscular dystrophy, with plans to proceed to Phase 2 trials focused on muscle regeneration.In oncology, Taiho and Cullinan's Phase 2 data on zipalertinib showed efficacy against EGFR-mutated non-small cell lung cancer with brain metastases. This advancement highlights the potential of tyrosine kinase inhibitors in precision oncology. Similarly, Arcus Biosciences reported a median survival of 26.7 months for its combination therapy with domvanalimab and zimberelimab in gastroesophageal adenocarcinoma trials, underscoring the promise of TIGIT-targeted therapies.Assembly Biosciences has shared promising Phase 1b results for its ABI-5366 helicase-primase inhibitor, achieving an impressive 94% reduction in herpes simplex virus shedding. OS Therapies reported significant survival improvement with its OST-HER2 vaccine in recurrent pulmonary metastatic osteosarcoma patients, positioning HER2-targeting immunotherapies as promising cancer treatment interventions.Cabaletta Bio has made strides with its resecabtagene autoleucel CAR-T therapy, demonstrating B cell elimination without preconditioning in pemphigus vulgaris trials. This innovation opens new doors for autoimmune disease management through advanced cell therapies.On the business development front, Roche's out-licensing of its GLP-1/GIP agonist CT-388 to Chugai for diabetes and obesity treatment exemplifies strategic partnerships focused on addressing metabolic disorders through novel small molecules.The sector is also witnessing significant financial activities with Evommune filing an IPO to advance treatments for inflammatory conditions. Meanwhile, Quoin Pharmaceuticals raised $104.5 million through private placement to concentrate on rare disSupport the show

Are you doing all the right things — eating well, balancing your hormones, supporting your gut, getting your steps in — but the scale still isn't budging?You're not crazy. You're not lazy. And you're definitely not alone.In this episode of The Period Whisperer Podcast, I'm diving into one of the most talked-about — and misunderstood — tools in midlife health: peptide therapy. Specifically, we're talking about GLP-1s and GLP-1/GIP + B12 blends, and how microdosing these peptides can help support your metabolism, energy, and weight loss without extreme diets or overexercising.I'll walk you through: ✨ What GLP-1 and GIP peptides actually are — and how they work with your body (not against it) ✨ The difference between traditional GLP-1s and the microdose GLP-1/GIP + B12 stack ✨ Why it's not cheating to get help supporting your metabolism in perimenopause ✨ The real reasons women get “stuck” with their weight in midlife — and how peptides can help rebalance blood sugar, reduce inflammation, and calm “food noise” ✨ Why microdosing is my preferred approach (plus the incredible results I've seen in my clients and my wife!) ✨ The foundational lab markers to check before starting any peptide protocolIf you've been feeling stuck — even though you're doing everything right — this episode will help you see why it's not your fault, and how science-backed peptide therapy might be the missing piece to help your body respond again.

W tym odcinku rozmawiamy z dr. Tadeuszem Oleszczukiem o tym, czym dziś jest mądre zdrowie: od kuchni i snu, przez mikrobiotę i hormony, po realia systemu ochrony zdrowia. Pytamy o dwa posiłki dziennie, cukier i żywność ultraprzetworzoną (UPF), czy „prawdziwy chleb” jeszcze istnieje i czym różni się rzemiosło od przemysłu (biopiekarz). Dyskutujemy o „jedzeniu jako lekarstwie”, wpływie nowych technologii na sen i apetyt, o zmianach jakości żywności i ich możliwym związku z płodnością oraz zdrowiem dzieci. Wchodzimy też w farmakoterapię: kiedy styl życia nie wystarcza, a kiedy warto rozważyć GLP‑1/GIP (np. Ozempic/Wegovy, tirzepatyd) — i jak łączyć leki z nawykami, by uniknąć nawrotów. Na koniec: jak żyć z dala od apteki, jakich leków OTC nadużywamy i jak rozsądnie korzystać z medycyny.

SUPPORT OUR WORK: OTPLinks.com

Recorded live at Leverage Fitness, so please excuse the background noise.                        Hear what we have to say about: Longevity - Lifespan vs Healthspan Taking a look inside - why getting more extensive bloodwork is vital Weight Loss simplified - calories in vs calories out Medications, Prescriptions and Dietary Aids - deciding which might be best for you Nutrtion - do you have to eat healthy to be healthy? Supplements - which are the most important to consider? Sleep - how does it affect weight, energy and recovery? Taking control when feeling overwhelmed  Gym myths     APEX RX https://apexrx.net   Jesse Frank https://www.lvrgfit.com jesse.dfrank@gmail.com   Charlie Seltzer https://drseltzerlifestylemedicine.com info@drseltzerweightloss.com

Welcome to The Peptide Podcast. In this episode, we're unpacking the latest on retatrutide and how it measures up against semaglutide and tirzepatide.  If you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  https://pepties.com/partners/ We'll look closely at what the studies tell us so far — from overall weight loss to reductions in visceral fat and how much lean muscle mass is preserved. We'll also talk about where the evidence is solid, where it's still developing, and why cross-trial comparisons should be made with caution. What is retatrutide? So let's start with the basics—what is retatrutide? Retatrutide is a new type of weight-loss medication called a triple agonist. That sounds fancy, but what it really means is that it targets three hormone receptors in the gut and pancreas: GLP-1, GIP, and glucagon. Each of these plays a slightly different role in metabolism and appetite regulation. To break it down: GLP-1, which you might already know from drugs like semaglutide, mainly slows digestion, helps you feel full, and improves insulin sensitivity. GIP, which tirzepatide targets along with GLP-1, also helps regulate blood sugar and may improve how the body stores and burns fat. Retatrutide adds glucagon receptor activation on top of that, which seems to further boost fat burning. So how does this compare to semaglutide and tirzepatide? Semaglutide is a GLP-1-only drug, so it mainly works by reducing appetite and slowing gastric emptying. Tirzepatide is a dual agonist, hitting GLP-1 and GIP, which gives it a slightly stronger effect on blood sugar control and fat metabolism compared to semaglutide. Retatrutide goes one step further by adding glucagon activity, potentially giving more total fat loss. In other words, you can think of it like a spectrum: semaglutide hits one target, tirzepatide hits two, and retatrutide hits three—each additional receptor seems to enhance metabolic effects and fat loss in clinical trials. That's why people are excited about retatrutide, though it's still early, and we're waiting on larger studies to see exactly how it compares head-to-head with the others. And that's going to be key, since right now we don't have direct comparisons to other advanced therapies like semaglutide or tirzepatide in the published Phase 2 data. How does retatrutide compare to semaglutide and tirzepatide? Total body weight loss: Now let's put these three medications side by side and look at what the trials actually tell us about total body weight loss. Starting with retatrutide: in its Phase 2 obesity program, the numbers were unusually large, especially given the relatively short trial window. In the 48-week study, people on the higher doses—8 or 12 milligrams weekly—lost about 22 to 24% of their body weight on average. That's the result that really made headlines. It's worth noting that some trials report slightly different averages depending on the group studied—people with obesity but no diabetes versus people with type 2 diabetes—but across the board, that 48-week signal is consistently very strong. For comparison, let's step back to semaglutide at the 2.4 mg dose, which was tested in the pivotal STEP-1 trial. Over 68 weeks, participants lost about 15% of their body weight on average. That was a landmark finding when it was published in the New England Journal of Medicine—it essentially set the modern benchmark for what a GLP-1 monotherapy could do. Then we have tirzepatide, the dual GIP and GLP-1 agonist. The SURMOUNT-1 trial, which ran for 72 weeks, showed dose-dependent results: about 15% weight loss at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, compared to only around 3% with placebo. Other obesity studies with tirzepatide have backed this up, especially at the higher doses. And in head-to-head comparisons with semaglutide, tirzepatide has consistently come out on top. So if we zoom out: retatrutide's Phase 2 data suggest the greatest average reductions—over 22%—in less than a year. Tirzepatide follows closely behind with around 21% over 72 weeks. And semaglutide shows very meaningful, but smaller, weight loss of around 15% over a similar time frame. The big caveat here is that these aren't perfect apples-to-apples comparisons. The trials differed in their length, the types of patients enrolled—some had type 2 diabetes, some did not—their baseline weights, and even the way results were reported. Plus, retatrutide is still in Phase 2 for obesity, whereas semaglutide and tirzepatide already have large Phase 3 programs and real-world data backing them up. Visceral fat reduction: Next, let's talk about visceral fat reduction—that's the deep fat that surrounds organs like the liver, pancreas, and intestines. It's particularly important because high levels of visceral fat are strongly linked to cardiometabolic disease. Starting with retatrutide, one of the Phase 2 substudies used DEXA scans to measure body composition in detail. At the higher doses—8 and 12 milligrams per week—participants saw visceral fat drop by about 29 to 31% over 48 weeks. That's a very large relative reduction in under a year and one of the reasons people are excited about retatrutide's potential not just for weight loss, but also for improving long-term metabolic health. How does that compare to the other drugs? With semaglutide, we also have DEXA and imaging substudies from the STEP program and follow-up mechanistic work. These consistently show meaningful visceral fat reductions, along with improvements in the ratio of lean to fat mass. The difference is that semaglutide studies typically report VAT changes as “significant and clinically relevant,” but they don't always publish one clear headline number that's directly comparable to retatrutide's ~30%. In other words, semaglutide definitely lowers visceral fat, but depending on the study and population, the exact percentage looks different. For tirzepatide, we also have imaging-based data from the SURMOUNT trials and related body-composition studies. These show that the majority of weight lost is fat mass—including a significant portion of visceral fat. Some analyses report reductions on par with what's seen with GLP-1 therapies, while others suggest tirzepatide may push a bit further. But again, the actual percentages vary depending on whether the study used DEXA, CT, or MRI, and on who was enrolled. The big caveat here is that we don't yet have a head-to-head imaging study comparing all three drugs in the same population with the same methods. Retatrutide's ~30% visceral fat drop is certainly eye-catching, but without that kind of standardized comparison, it's hard to say definitively whether it's truly better than semaglutide or tirzepatide. Lean muscle mass preservation: Now let's shift to lean mass preservation, which is just as important as total weight or fat loss. Across all of the modern obesity drug trials, one thing has been consistent: most of the weight people lose is fat, but some lean tissue is lost too. That's expected whenever you're in a sustained calorie deficit. The question is how much muscle is preserved, and how the proportions break down. With retatrutide, the DEXA substudy showed something reassuring. Even though people lost a lot of total weight and fat, the proportion of lean mass lost compared to total weight loss was similar to what we see with other therapies. In other words, the drug seems to drive large fat reductions without causing disproportionate muscle loss. Interestingly, the absolute amount of lean tissue lost in kilograms was pretty stable across different doses, even though fat loss varied quite a bit. That suggests the extra weight loss with higher doses is really coming from fat, not muscle. Looking at semaglutide, the STEP trials with DEXA scans reported the same general pattern. People lost more fat than lean mass, and when you adjust for the total weight loss, body composition actually improved. In fact, some analyses showed a slight increase in the percentage of body weight that was lean tissue, even though the absolute lean mass in kilograms went down. So again, it's not that muscle isn't affected—it is—but fat loss makes up the majority of the change. For tirzepatide, the SURMOUNT body-composition studies found that about 75% of the weight lost is fat and about 25% is lean mass. That split is very similar to what was seen in the placebo groups, which means the drug isn't shifting the balance unfavorably. It preferentially reduces fat, while lean mass preservation is in the same ballpark as semaglutide and retatrutide. Now, here's the important nuance: lean mass on a DEXA scan isn't just skeletal muscle. It includes water, organ tissue, and other components. So if someone loses 3 or 4 kilograms of “lean mass,” we don't know how much of that is functional muscle versus water or smaller organ size. That's why these numbers can be misleading if you take them at face value. And this is where lifestyle comes in. Resistance training and adequate protein intake are critical alongside medication. Lifting weights or doing bodyweight resistance work helps preserve functional muscle, while getting enough protein—typically somewhere in the range of 0.8 to 1 gram per pound per day depending on age and activity—supports muscle repair and maintenance. Every trial we've seen shows that the best outcomes, in terms of maintaining strength and function, come from pairing these drugs with exercise and nutrition strategies. That way, the unavoidable lean mass changes have far less impact on long-term metabolic health and performance. Limitations, biases, and what's missing (the critical context). No large, peer-reviewed head-to-head trials (yet) comparing retatrutide with semaglutide or tirzepatide for the same endpoints using identical imaging protocols. Most comparisons are cross-trial and therefore imperfect. Retatrutide Phase-2 was often compared to placebo or dulaglutide (in the T2D DEXA substudy) rather than to semaglutide or tirzepatide. A head-to-head (planned/registered) study vs tirzepatide is listed on ClinicalTrials.gov but results are not published yet. Different populations & durations. Some retatrutide data come from cohorts that include people with T2D or NAFLD; semaglutide STEP trials were often in people with obesity (without diabetes) and run longer (68 weeks), while tirzepatide SURMOUNT trials ran to 72 weeks. These differences change the absolute and percent outcomes. Funding and reporting bias. Many of the early retatrutide analyses are industry-funded (Eli Lilly), which is standard for drug development, but it requires us to carefully read methods, endpoints, and completeness of reporting. Independent replication and Phase-3 confirmation matter. Imaging method variation. VAT reported by DXA vs MRI vs CT are not directly interchangeable. Some trials report VAT area, others percent change; that complicates cross-trial percent comparisons.  Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend. Until next time, be well, and as always, have a happy, healthy week.

In this episode of The Health Revival Show, Liz & Becca break down Retatrutide—a new GLP-1, GIP, and glucagon receptor agonist that's making waves in the functional health and metabolic space. Is it really “Ozempic on steroids”? They cut through the hype and bring the context no one's talking about—the importance of muscle preservation, insulin sensitivity, thyroid health, and how to use these tools responsibly (or if at all). Whether you're considering peptides or just curious about this next-gen weight loss compound, this episode delivers the no-BS truth.

In this episode, I share some thoughts on managing hunger.. both when you're in a calorie deficit and in everyday life.We'll talk about what drives hunger (like leptin, ghrelin, and even GLP-1/GIP meds), why it ramps up during dieting, and simple ways to keep it in check through food choices, lifestyle habits, and mindset shifts.If hunger has been making things harder than they need to be, this one's for you.Where to find me:IG: @lukesmithrdCheck out my website HEREFill out a 1:1 coaching application HERE

Sick of trying fad diets that just don't seem to work for you? Find out how to simplify your approach and succeed by learning and applying the principles of weight management.  How to make calories work for you Which proteins are better than others and when to eat protein Preserving lean muscle while losing body fat "Dirty" vs "Clean" diets Including desert and candy during a weight loss journey   APEX RX https://apexrx.net   Jesse Frank https://www.lvrgfit.com jesse.dfrank@gmail.com   Charlie Seltzer https://drseltzerlifestylemedicine.com info@drseltzerweightloss.com

In this emotional Flashback Friday episode of The Radio Vagabond, I travel to Bessemer, Alabama to experience Gip's Place  –  a legendary juke joint founded in the backyard of Henry “Gip” Gipson. At the time, Gip was an astonishing 97 years old, still hosting Saturday night blues sessions in his tin-roofed music shed alongside family, locals, and wandering musicians. His motto, “No black, no white, just blues,” resonated through every note. Update: Sadly, Henry “Gip” Gipson passed away on October 8, 2019, at the age of 99, closing a chapter on one of America's last authentic juke joints. See pictures and read more on https://www.theradiovagabond.com/066-alabama/ This Flashback Friday episode was first released on March 15, 2019.

In this emotional Flashback Friday episode of The Radio Vagabond, I travel to Bessemer, Alabama to experience Gip's Place  –  a legendary juke joint founded in the backyard of Henry “Gip” Gipson. At the time, Gip was an astonishing 97 years old, still hosting Saturday night blues sessions in his tin-roofed music shed alongside family, locals, and wandering musicians. His motto, “No black, no white, just blues,” resonated through every note. Update: Sadly, Henry “Gip” Gipson passed away on October 8, 2019, at the age of 99, closing a chapter on one of America's last authentic juke joints. See pictures and read more on https://www.theradiovagabond.com/066-alabama/ This Flashback Friday episode was first released on March 15, 2019.

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this episode of The Wright Report, we cover the shocking assassination of Charlie Kirk, Russian drones breaching NATO airspace, Trump's war on Venezuela's cartels, Mexico's tariff fight with China, a pharmaceutical victory in Tennessee, and new revelations in the 9/11 families' lawsuit against Saudi Arabia. From political violence at home to dangerous escalations abroad, today's brief carries heavy news on a day of prayer and remembrance.   Charlie Kirk Assassinated in Utah: The 31-year-old Turning Point USA founder was gunned down while speaking at Utah Valley University. President Trump called him “a martyr for truth and freedom” and ordered flags at half-staff. Video shows a sniper shot to the neck from a rooftop as Kirk addressed thousands of students. MSNBC sparked outrage with coverage that suggested Kirk's “awful words” made his death inevitable. Bryan warns, “The seal has now been broken: if you make those arguments or say those words, you're fair game too.”   Russian Drones Violate Polish Airspace: NATO confirms 19 Russian drones flew over 150 miles into Poland, with several shot down by Dutch and Polish jets. Bryan cautions that even an accident could spark a “Gulf of Tonkin–like incident” dragging NATO into direct war with Moscow.   Trump Escalates War on Venezuela's Cartels: After U.S. forces sank a drug boat killing 11, critics accuse Trump of overstepping presidential authority. War Secretary Pete Hegseth countered: “This strike sent a clear message: If you traffic drugs toward our shores, the United States military will stop you cold.”   Mexico Tariffs Chinese Imports: President Claudia Sheinbaum hikes tariffs on Chinese cars and textiles to 50 percent, aiming to shield Mexican workers and appease Trump's demands to close tariff loopholes. Bryan notes this could undercut Beijing's backdoor into U.S. markets.   Saving U.S. Antibiotics in Tennessee: Trump brokers a deal forcing Walmart and McKesson to buy amoxicillin from Bristol, Tennessee, rescuing America's last antibiotic factory from collapse. “Don't bet against America,” Bryan says, “because with leadership that actually loves this country, we will win.”   9/11 Families' Lawsuit Against Saudi Arabia Advances: A New York judge allows families to pursue claims that Saudi intel officers Omar al-Bayoumi and Fahad al-Thumairy aided hijackers. ProPublica reports al-Bayoumi was a Saudi intel asset in the U.S. coordinating with the GIP. Bryan calls for Trump to declassify CIA files: “It's time for some sunlight on what did or didn't happen that horrific day.”   "And you shall know the truth, and the truth shall make you free." - John 8:32     Take your personal data back with Incogni! Get 60% off an annual plan at incogni.com/TWR and use code TWR at checkout.     Keywords: Charlie Kirk assassination Utah, Trump martyr for truth, MSNBC Charlie Kirk coverage, Russian drones Poland NATO, Trump Venezuela drug cartels strike, Pete Hegseth drug cartels al Qaeda, Mexico tariffs Chinese imports Sheinbaum, Trump tariff war China backdoor, U.S. antibiotics Bristol Tennessee amoxicillin, Walmart McKesson Trump drug deal, 9/11 families lawsuit Saudi Arabia, Omar al-Bayoumi Saudi intel, Fahad al-Thumairy Saudi cleric, CIA Saudi 9/11 declassification

Per ben quattro volte il GIP di Reggio Calabria respinge le richieste di archiviazione della procura, chiedendo nuove indagini ed esami, dando vita così ad una guerra di perizie tra la procura e la famiglia di Fausto. Strane macchie di sangue, autopsia svolta dopo tre anni dalla morte e un insieme di dettagli che stonano con la ricostruzione suicidaria. La verità sembra a portata di mano ma ogni giorno sembra anche allontanarsi sempre di più mentre la famiglia, a distanza di nove anni, sta ancora lottando in cerca di verità e giustizia per il proprio figlio.See omnystudio.com/listener for privacy information.

Today we're diving into a topic that a lot of people struggle with quietly but don't always feel comfortable talking about: food anxiety. And if you want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Maybe you've felt nervous about going to a party because you weren't sure what kind of food would be there. Or maybe you've found yourself planning your entire day around what you'll eat and how to control it. Perhaps you've even finished a meal only to have guilt set in right away. That's what food anxiety looks like—and you are definitely not alone. Today we're going to talk about what food anxiety actually is, why it shows up, what you can do to calm it, and even how some of the newest medications—things like GLP-1s and dual GIP/GLP-1s—may actually help by quieting some of the mental “food noise.” What is food anxiety? At its core, food anxiety is stress or fear around eating. And the thing is, it doesn't look the same for everyone. For one person, it might show up as constantly worrying they'll overeat. For another, it's that lingering guilt after eating something they feel they “shouldn't have.” And sometimes it's more subtle than that—like a constant hum in the background of your mind where you're thinking about food all day, even when you're not hungry. I often describe it like having a radio station in your brain that's tuned into “food talk.” Sometimes it's background noise, sometimes it's blaring, but either way, it's draining. And over time, that stress around eating chips away at both your mental and physical health. Why does food anxiety happen? So why does this happen in the first place? A big part of it is the culture we live in. For decades, we've been bombarded with messages that carbs are bad, fat is bad, sugar is the enemy—and the list keeps changing. That constant labeling of food as “good” or “bad” teaches us to feel guilty when we eat the so-called wrong thing. For others, food anxiety starts when they get a medical diagnosis. If you've been told you have diabetes, heart disease, or that you need to lose weight for health reasons, suddenly every single bite can feel like a math problem. You're not just eating—you're calculating, you're worrying, you're second-guessing. And then there's the way dieting itself messes with our natural signals. When we spend years restricting, counting, and controlling, we often lose touch with our body's hunger and fullness cues. Instead of trusting how we feel, we rely on rigid rules. And when those rules get broken, the anxiety hits hard. And finally, we can't ignore biology. Food, especially highly processed food, lights up reward pathways in the brain. For some people, those signals are incredibly strong—stronger than for others. That means more cravings, more urges, and unfortunately, more guilt when they give in. What can you do about food anxiety behaviorally? Now, here's the good news. There are things you can do to reduce food anxiety, and you don't need to overhaul your entire life to start seeing changes. One of the simplest but most powerful tools is mindful eating. And I know that phrase gets thrown around a lot. But at its heart, mindful eating just means slowing down.  It means actually tasting your food, noticing the textures, and checking in with how your body feels. When you slow down enough to notice satisfaction, you're much more likely to stop eating when you're comfortable instead of stuffed—and that takes a lot of the stress out of the meal. Another shift that helps tremendously is dropping the “good” and “bad” food labels. Health isn't decided by one cookie, just like it isn't guaranteed by one salad. What matters is your overall pattern, week by week, month by month. When you start to see food as neutral—as fuel, as enjoyment, as part of life—it loosens the grip of guilt and allows you to be more flexible. And speaking of flexibility, having a loose structure around meals can be calming. Instead of rigid dieting rules, like “I can never eat after 7 p.m.,” focus on balance. A meal that has some protein, some fiber, and a little healthy fat is naturally stabilizing. It helps keep blood sugar steady, which means fewer spikes and fewer crashes. And when your body feels stable, your brain feels calmer, too. It's also worth paying attention to your personal triggers. For some people, weekly weigh-ins, keeping a food log, or using a nutrition app can be helpful. But for others, they actually fuel the anxiety. If you notice those things making you more stressed rather than less, it's okay to step away from them. You can still eat intentionally without logging every single bite. And while we are on the subject of personal triggers like daily or weekly weigh-ins, I want to talk about this a bit more. It's really important to remember, your body weight naturally fluctuates from day to day. Daily weight changes are completely normal and can happen for a bunch of reasons.  Your body might hold onto water from salty foods, hormones, or just changes in hydration. What you've eaten recently can also temporarily add weight, and when you eat carbohydrates, your muscles store them along with water, which can make the scale go up a bit. For women, hormonal changes during the menstrual cycle can cause water retention that shows on the scale as well. On top of all that, if you've been exercising more, you might be building muscle even while losing fat. Because muscle is denser than fat, the scale might not move—or could even go up slightly—while your body is actually getting leaner and stronger. Because of these normal variations, seeing a slightly higher number on the scale one day can feel discouraging—even if you're making great progress. Instead of focusing on daily fluctuations, a better approach is to look at your net overall trend over a month. Tracking the weekly or monthly average gives you a more accurate picture of real progress and helps reduce stress or obsession with the number on the scale And lastly, support makes a big difference. Whether that's working with a dietitian, talking with a therapist, or joining a group, sometimes having someone else in your corner makes it easier to change both your habits and the way you think about food. Where medications may help: GLP-1s and dual GIP/GLP-1s Now let's shift gears for a moment, because in the past few years, there's been an exciting development in how we treat weight and appetite. Medications like GLP-1 receptor agonists—semaglutide is one example—and the newer dual GIP/GLP-1 agonists, like tirzepatide, have been game changers. So what do they actually do? GLP-1s mimic a natural hormone your gut makes after you eat. That hormone tells your brain, “Hey, you're full.” It also slows down how quickly food leaves your stomach and helps keep you fuller, longer. They also cause your pancreas to release insulin when there's too much sugar from food in your bloodstream. This lowers your blood sugar and helps your cells use glucose (sugar from the food you've eaten). This is helpful because extra sugar your cells don't use for energy is stored as fat, which is why high blood sugar can cause weight gain.  The dual GIP/GLP-1s do all of that, plus they act on another hormone called GIP, GIP improves how your body uses sugar AND fat (storing less of both by breaking them down to use for energy). Now, here's where it gets fascinating for food anxiety. People who take these medications often report that the “food noise” in their head finally quiets down. Instead of thinking about food all day, the volume on that radio station turns way down. Meals feel more manageable. A normal portion actually feels satisfying. And for many, that overwhelming urge to snack or binge just isn't there anymore. When your hunger cues are more predictable and less intense, you don't feel like you're constantly fighting your own body. That alone can dramatically reduce the anxiety around eating. And by calming the physical side—the cravings, the urges—it gives you more space to work on the mental and emotional side of eating without feeling like you're swimming upstream. Of course, these medications aren't a magic fix. They don't erase years of learned guilt or change the culture we live in. But they can be powerful tools, especially when paired with mindful eating practices and professional support. My Final Thoughts If you take one thing away from this episode, let it be this: food anxiety is real. It's not about weakness or lack of willpower. It's shaped by culture, by biology, by personal history—and it can be incredibly challenging. But there are ways to reduce it. Slowing down and being more mindful at meals, letting go of the “good food versus bad food” mindset, building flexible eating habits, and getting support are all steps in the right direction. And for some, medications like GLP-1s or dual GIP/GLP-1s can make the process easier by quieting the biological noise that drives anxiety in the first place. Thanks for listening to The Peptide Podcast. If today's episode resonated, share it with a friend and please remember you're not alone. Many people struggle with food anxiety, and there is nothing wrong with reaching out for help—whether that's behavioral support, medical treatment, or both. Until next time, be well, and as always, have a happy, healthy week.  

Episode 311 showcases our hosts Dr Jake Sloane & David Segal. In our 'What's trending in Aesthetics?' episodes we discuss popular topics doing the rounds on social media, issues being debated in injector forums or items showcased on the news. We'll cover controversies, big stories and themes that have got injectors and our industry talking. In Chapter 14 our hosts Dr Jake and David explore: the global rise in the use of GLP-1 medications the impact of the 'Trump tariffs' with a huge price hike of Mounjaro (GLP-1/GIP medicine) in the UK - and the implications on the pricing of aesthetic products in the future Kris Jenner's recent facelift and whether not looking your age is the new 'normal' a new on label indication for Botox (platysmal bands of the neck) and why injectors can't afford to ignore this region 00:00 Introduction to Inside Aesthetics 00:47 Welcome to the New Podcast Studio 01:29 Upcoming Conferences and Events 06:26 Exploring GLP-1: The Wonder Drug for Weight Loss 10:28 The Impact of GLP-1 on Aesthetic Practices 21:45 Price Hike in Weight Loss Drugs 23:42 Discussing Botox Price Hike Concerns 24:16 Understanding Gross Margins in Business 24:54 Promoting Our Patreon and Resources 25:17 Price Discrepancies in Pharmaceuticals 26:46 Celebrity Facelifts: The Case of Kris Jenner 28:05 Defining 'Natural' in Cosmetic Surgery 31:25 Combination Treatments for Best Results 37:35 New Trends in Botox Indications 38:36 Improving Consultation Processes 45:10 Concluding Remarks and Contact Information   CLICK HERE TO JOIN OUR PATREON FOR ON DEMAND EDUCATION & SUPPORT CLICK HERE TO BROWSE OUR IA OFFERS FOR DISCOUNTS & SPECIALS CLICK HERE IF YOU'RE A BRAND OR COMPANY & WANT TO WORK WITH US CLICK HERE TO APPLY TO BE A GUEST ON OUR PODCAST JOIN OUR LISTENER WHATSAPP GROUP & SEND US YOUR COMMENTS, SUGGESTIONS OR JUST SAY HI! CONTACT US  

Liver, Lipids, and the Left Ventricle

Voor de seizoensfinale en de 100ste aflevering in Nederland (JA JA MENSEN) blijven we in het Fochteloërveen want de koek is nog lang niet op. Gip heeft nog nooit echt goed een slangenarend gezien dus dat is de doelsoort. Maar ook de wielewaal is weer in het land en het gejodel klinkt al uit de bomen. Het zien is alleen een tweede bij deze vogel. Daarnaast is het lievelingsvogeltje van Arjan ook aanwezig; het paapje. Kortom, het wordt een heerlijke vogeldag vol met verassingen.Zie het privacybeleid op https://art19.com/privacy en de privacyverklaring van Californië op https://art19.com/privacy#do-not-sell-my-info.

We begin Adventure August by bringing you something from the past and we are MANIC! A visit from our very own lost girl had us bangerang as little hair, big teeth Tink gets swole, we consider the origin of bar eggs, lil' Amber Scott's lack of link, a check being a check and a fart being a fart and granny Wendy being a FREAK. Her and Toodles? Girl, no - Girl, yes! Don't be stingy, get dusty for PeterGet yer ship and GIP! It's Hook, this week on Doom Generation! Support this podcast at patreon.com/doomgeneration

This episode reveals groundbreaking 2025 research that will revolutionize how you approach OMAD (One Meal A Day) fasting. Dr. Scott and Tommy break down a game-changing study showing how your pre-fast meal composition dramatically affects ketosis timing and fat burning efficiency during 24-hour fasts. Discover the shocking difference between starting a fast with a low-carb, high-fat meal versus a high-carb, low-fat meal: the low-carb group reached nutritional ketosis by hour 12, while the high-carb group never achieved ketosis during the entire 24-hour period. Learn how the right pre-fast meal drops insulin by 42% within one hour, increases fat-burning hormone glucagon by 24%, and naturally boosts GLP-1 (the "Ozempic hormone") by 27% and GIP by 34.5% - giving you natural appetite suppression and metabolic enhancement. The hosts explain why this simple meal composition change (60% fat, 30% protein, 10% carbs versus the opposite) can be the difference between plateau frustration and consistent fat loss results. Understand why your dinner OMAD might be sabotaging your progress, how meal timing amplifies these effects, and practical food swaps to optimize your pre-fast nutrition. If you're stuck in the 3-5 pound weight fluctuation cycle despite consistent OMAD fasting, this episode provides the missing piece to unlock sustained ketosis and accelerated fat burning. Essential listening for anyone wanting to maximize their OMAD strategy and achieve consistent, sustainable results without longer fasts or extreme measures. ⁠⁠Take the NEW FASTING PERSONA QUIZ! - The Key to Unlocking Sustainable Weight Loss With Fasting!⁠⁠⁠ Resources and Downloads: ⁠⁠⁠SIGN UP FOR THE DROP OF THE ULTIMATE GUIDE TO BLOOD SUGAR CONTROL⁠⁠⁠ ⁠⁠⁠GRAB THE OPTIMAL RANGES FOR LAB WORK HERE! - NEW RESOURCE! ⁠ ⁠⁠⁠FREE RESOURCE - DOWNLOAD THE NEW BLUEPRINT TO FASTING FOR FAT LOSS!⁠⁠⁠ ⁠⁠⁠SLEEP GUIDE DIRECT DOWNLOAD⁠⁠⁠ ⁠⁠⁠DOWNLOAD THE FASTING TRANSFORMATION JOURNAL HERE!⁠⁠⁠ Partner Links: Get your⁠⁠⁠ FREE BOX OF LMNT⁠⁠⁠ hydration support for the perfect electrolyte balance for your fasting lifestyle with your first purchase⁠⁠⁠ here!⁠⁠⁠ Get ⁠⁠⁠30% off a Keto-Mojo⁠⁠⁠ blood glucose and ketone monitor (discount shown at checkout)! ⁠⁠⁠Click here!⁠⁠⁠ Our Community: Let's continue the conversation. Click the link below to JOIN the ⁠⁠⁠Fasting For Life Community⁠⁠⁠, a group of like-minded, new, and experienced fasters! The first two rules of fasting need not apply! If you enjoy the podcast, please tap the stars below and consider leaving a short review on Apple Podcasts/iTunes. It takes less than 60 seconds, and it helps bring you the best original content each week. We also enjoy reading them! Article Links: https://pmc.ncbi.nlm.nih.gov/articles/PMC11998415/pdf/12986_2025_Article_920.pdf